Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Small cell lung carcinoma (SCLC) is a highly aggressive neoplasm, which accounts for approximately 25% of all lung cancer cases. Molecular mechanisms altered in SCLC include induced expression of oncogene, MYC, and loss of tumorsuppressor genes, such as p53, PTEN, RB, and FHIT. The overexpression of MYC proteins in SCLC is largely a result of gene amplification. Such overexpression leads to more rapid proliferation and loss of terminal differentiation. Mutation or deletion of p53 or PTEN can lead to more rapid proliferation and reduced apoptosis. The retinoblastoma gene RB1 encodes a nuclear phosphoprotein that helps to regulate cell-cycle progression. The fragile histidine triad gene FHIT encodes the enzyme diadenosine triphosphate hydrolase, which is thought to have an indirect role in proapoptosis and cell-cycle control.
Category
Cancer
Brite
Human diseases in ICD-11 classification [BR:br08403]
02 Neoplasms
Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues
Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues
Malignant neoplasms of middle ear, respiratory or intrathoracic organs
2C25 Malignant neoplasms of bronchus or lung
H00013 Small cell lung cancer
Pathway-based classification of diseases [BR:br08402]
Signal transduction
nt06526 MAPK signaling
H00013 Small cell lung cancer
Cellular process
nt06512 Chromosome cohesion and segregation
H00013 Small cell lung cancer
nt06524 Apoptosis
H00013 Small cell lung cancer
Tumor markers [br08442.html]
H00013
Cancer-associated carbohydrates [br08441.html]
H00013
